Skip to main contentSkip to navigationSkip to search


Addressing important unmet medical needs

Our products

Camurus' products are based on our proprietary FluidCrystal® technology and are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery.

opioid dependence

Buvidal® prolonged-release solution for injection

Buvidal® buprenorphine injection depot is indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment, and intended for use in adults and adolescents aged 16 years or over.

Buvidal is based on Camurus' proprietary FluidCrystal injection depot technology and is intended for weekly or monthly administration by healthcare professionals. 

More information on (for healthcare professionals)


Brixadi® (buprenorphine) extended-release for subcutaneous use

Brixadi (buprenorphine) extended-release injection for subcutaneous use is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Brixadi should be used as part of a complete treatment plan that includes counselling and psychosocial support.

Brixadi is the US trademark for Camurus’ product Buvidal. The product rights to Brixadi in North America are licensed to Braeburn by Camurus.

More information on Brixadi (for US healthcare professionals)